Measurement of sitafloxacin MIC for Myco bacterium avium complex and application for treatment of pulmonary nontuberculous mycobacteriosis

Masaki Fujita, Takemasa Matsumoto, Ryousuke Hirano, Eul Harada, Satoshi Ikegame, Yoichi Naicnishi, Kentaro Watanabe

Research output: Contribution to journalArticle

1 Citation (Scopus)


Treatment for pulmonary nontuberculous mycobacteriosis is difficult. Since current treatment has limitation, new application is needed. Fluoroquinolone is one of candidates. We have investigated the feasibility of sitafloxacin (STFX). At first, the drug of MIC (minimum inhibitory concentration) was determined by the methods based on BrothMIC NTM. The MICs of STFX, moxifloxacin (MFLX), gatifioxacin (GFLX) were low. On contrast, the MICs of garenoxacin (GRNX) and tosufloxacin (TFLX) were high. Two cases of pulmonary Mycobacterium avium-intracellulare complex (MAC) disease were treated by STFX-contained regimen. In all cases of pulmonary MAC disease, improve of symptoms and chest CT images were attained. Adverse events were slight. These MIC studies and case reports suggest that STFX might have excellent in vitro and in vivo antimicrobial activities against MAC and is considered to be a candidate for the medication against pulmonary MAC disease.

Original languageEnglish
Pages (from-to)395-400
Number of pages6
JournalJapanese Journal of Antibiotics
Issue number6
Publication statusPublished - Dec 1 2014


All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this